Literature DB >> 15300976

Beneficial response to interleukin 1 receptor antagonist in traps.

Anna Simon, Evelien J Bodar, Jeroen C H van der Hilst, Jos W M van der Meer, Theo J W Fiselier, Marcel P J M Cuppen, Joost P H Drenth.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15300976     DOI： 10.1016/j.amjmed.2004.02.039

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  42 in total

1.  Effects of the histone deacetylase inhibitor ITF2357 in autoinflammatory syndromes.

Authors:  Evelien J Bodar; Anna Simon; Jos W M van der Meer
Journal:  Mol Med       Date:  2011-01-25       Impact factor: 6.354

Review 2.  [Translational research in pediatric rheumatology. Current research approaches to the innate immune system].

Authors:  K Lippitz; J Waldkirch; C Kessel; G Varga; D Foell
Journal:  Z Rheumatol       Date:  2016-04       Impact factor: 1.372

Review 3.  Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1.

Authors:  R Goldbach-Mansky
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

4.  Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study.

Authors:  Ariel C Bulua; Douglas B Mogul; Ivona Aksentijevich; Harjot Singh; David Y He; Larry R Muenz; Michael M Ward; Cheryl H Yarboro; Daniel L Kastner; Richard M Siegel; Keith M Hull
Journal:  Arthritis Rheum       Date:  2012-03

5.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 6.  Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).

Authors:  Francesco La Torre; Maurizio Muratore; Antonio Vitale; Fulvio Moramarco; Laura Quarta; Luca Cantarini
Journal:  Rheumatol Int       Date:  2015-06-06       Impact factor: 2.631

Review 7.  Current knowledge on procaspase-1 variants with reduced or abrogated enzymatic activity in autoinflammatory disease.

Authors:  Hella Luksch; Stefan Winkler; Michael C Heymann; Felix Schulze; Sigrun R Hofmann; Joachim Roesler; Angela Rösen-Wolff
Journal:  Curr Rheumatol Rep       Date:  2015-07       Impact factor: 4.592

Review 8.  Autoinflammation: translating mechanism to therapy.

Authors:  Taylor A Doherty; Susannah D Brydges; Hal M Hoffman
Journal:  J Leukoc Biol       Date:  2011-02-17       Impact factor: 4.962

Review 9.  Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses.

Authors:  Raphaela Goldbach-Mansky; Daniel L Kastner
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

Review 10.  Therapy of autoinflammatory syndromes.

Authors:  Hal M Hoffman
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.